There are close to 100 therapies in the pipeline for eczema: therapies with potential to help symptoms such as itch and redness, improve the skin barrier and ...

Aug 17, 2020 ... Given the tremendous burden of AD on physical, mental, and social health, the need is high to develop new, targeted therapies.

Dec 5, 2023 ... VTAMA (tapinarof), a new nonsteroid topical cream developed by Dermavant Sciences, is anticipated to be filed with the FDA in Q1 2024. VTAMA 1% ...

Apr 18, 2023 ... Dupilumab. Dupilumab is the first biologic drug approved for the treatment of moderate-to-severe AD in adults and adolescents by the US Food and ...

May 15, 2024 ... Other options for severe eczema. The injectable biologics (monoclonal antibodies) dupilumab (Dupixent) and tralokinumab (Adbry) might be options ...

Crisaborole 2% ointment, the first topical PDE4 inhibitor, was licensed by the FDA in December 2016 for the treatment of mild-to-moderate AD in children 2 years ...

Dec 9, 2022 ... The results support rocatinlimab as a safe and effective treatment for moderate to severe atopic dermatitis, with potentially long-lasting ...

Jan 8, 2024 ... Herein, we give an update on new approvals, long-term safety, and efficacy. Upadacitinib and abrocitinib have the highest short-term efficacy ...

Jul 10, 2014 ... ... medications (glucocorticoids and calcineurin inhibitors). ... new biologic therapy beyond asthma to a second atopic disorder, atopic dermatitis.

Nov 7, 2023 ... Dupilumab and tralokinumab are food and drug administration (FDA)-approved biologics for AD in adults. Dupilumab is a monoclonal antibody ...